Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 11, 2024Frontiers in OncologyOpen Access

Real-world evidence on tagraxofusp for blastic plasmacytoid dendritic cell neoplasm – collected cases from a single center and case reports

View Full Paper
Ask AI
Bookmark
Share

Authors

PFPhilipp FaustmannJSJan C. SchroederLMLucas Mix

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Faustmann et al. (2024) studied this question.

synapsesocial.com/papers/68e6f84ab6db643587672bc9https://doi.org/10.3389/fonc.2024.1384172
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world study of tagraxofusp monotherapy in relapsed or refractory blastic plasmacytoid dendritic cell neoplasm2025
  2. 2Real-world study of tagraxofusp monotherapy in relapsed or refractory blastic plasmacytoid dendritic cell neoplasm2025
  3. 3Hematopoietic effects of tagraxofusp in treatment‐naive patients with blastic plasmacytoid dendritic cell neoplasm2026 · 5 citations
  4. 4Sustained response to minimal-dose tagraxofusp in a patient with BPDCN and advanced chronic kidney disease2026 · 2 citations
  5. 5Overcoming Tagraxofusp-Erzs Monotherapy Resistance in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) in a Real-World Clinical Setting2024 · 3 citations